BIVIW — BIOVIE INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1580149 ·
Last close
$0.28
Market Cap
—
52W High
$0.28
52W Low
$0.28
ADV30
24,496
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,719,456 | -5,645,532 | 14,250,462 | 8,977,370 | 3,980,192 |
| Mar 2026 | 0 | — | -5,385,377 | -5,270,299 | 17,514,621 | 13,098,976 | 1,907,029 |
| Dec 2025 | 0 | — | -6,262,305 | -6,069,475 | 22,503,293 | 20,540,585 | 3,238,259 |
| Sep 2025 | 0 | — | -5,284,595 | -5,087,557 | 26,820,098 | 24,978,302 | 1,899,094 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,510,667
Investing CF
$0
Financing CF
$10,457,629
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-368,615,121
Inventory
—
Receivables
$2,173,684
ST Investments
—
EBIT TTM
$-19,897,551
Pretax Income TTM
$-19,916,472
Interest Exp TTM
$18,921
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | -22,651,733 | -22,072,863 | 14,250,462 | 3,980,192 | 10,270,270 | -19,024,806 |
| Jun 2025 | 0 | -18,066,200 | -17,542,120 | 21,562,199 | 2,550,214 | 19,011,985 | -19,025,205 |
| Jun 2024 | 0 | -32,179,585 | -32,120,533 | 25,208,345 | 9,702,130 | 15,506,215 | -27,945,024 |
| Jun 2023 | 0 | -45,080,448 | -50,255,815 | 35,104,730 | 19,764,444 | 15,340,286 | -40,252,881 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1184.78 | — |
| JNJ | JOHNSON & JOHNSON | $655.37B | $271.95 | — |
| ABBV | AbbVie Inc. | $470.55B | $266.28 | — |
| MRK | Merck & Co., Inc. | $366.84B | $148.69 | — |
| NVS | NOVARTIS AG | $279.18B | $146.88 | — |
News headlines (Yahoo Finance, 1h cache)
BioVie completes final patient visit in Phase 2 Long COVID trial
2026-08-31 13:05 · Yahoo
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
2026-08-31 12:00 · Yahoo
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-08-14 13:00 · Yahoo
Parkinson's drug developers are betting big on inflammation
2026-08-07 17:13 · Yahoo
Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results
2026-08-07 13:00 · Yahoo
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim
2026-08-06 13:03 · Yahoo
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
2026-08-06 11:30 · Yahoo
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
2026-09-26 14:28 · Yahoo
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
2026-09-19 15:45 · Yahoo
Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-09-18 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.